DMS Imaging S.A.
DMS Imaging S.A. (0RGO.L) Stock Overview
Explore DMS Imaging S.A.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
78.7K
P/E Ratio
-0.07
EPS (TTM)
$0.18
ROE
-0.11%
0RGO.L Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of DMS Imaging S.A. (0RGO.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 100.00, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $0.02.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.07 and a market capitalization of 78.7K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
DMS Imaging SA, a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen. The company is also developing hdm-ASIT+ for the treatment of house dust mite allergy; and pnt-ASIT+ for the treatment of peanut allergy. The company was formerly known as ASIT Biotech S.A. and changed its name to DMS Imaging SA in February 2022. DMS Imaging SA was incorporated in 1997 and is based in Liege, Belgium.
Samuel Sancerni
122
7 Rue des Chasseurs Ardennais, Liège
2023